Preliminary Results of Adding Meglumine Sodium Succinate to the Treatment of Patients with Moderate to Severe Acute Pancreatitis

Objective: to develop criteria of inclusion/noninclusion of patients for further randomized clinical trial of meglumine sodium succinate in patients with acute pancreatitis based on analysis of individual outcomes.

Material and methods. The efficacy of treatment of patients with moderate-to-severe and severe acute pancreatitis (n=100, 23–65 years old) with meglumine sodium succinate (intravenous drip infusions, 10 ml/kg daily, for 11 days) was assessed. Data were collected by 10 medical centers as a part of an observational program developed in accordance with the requirements of the Guidelines and Clinical Trial Committee of the AllRussia Public Organization «Federation of Anesthesiologists and Reanimatologists» (FAR) and approved by local ethical committees of the institutions. Treatment was prescribed in accordance with national and international standards. The patients were divided into two groups based on the outcome: group 1 (n=81) included patients who survived, while the patients of group 2 (n=19) died. We analyzed demographic characteristics of the groups, life and illness history, physical examination, routine laboratory and instrumental investigation data. The obtained results were statistically analyzed.

Results. We identified several factors occurring during hospitalization and/or transfer to intensive care unit (ICU), which could be predictors of adverse outcome and had varying impact on the risk of death in patients treated with the study drug. High-risk factors included stupor, platelet count below 248.5×10⁹/l, base excess (BE) less than -2.9 mmol/l, and urea above 11.85 mmol/l. Risk factors included body temperature below 37.1°C, plasma creatinine above 237 µmol/l, and glucose above 9.45 mmol/l. Mottled skin and plasma ionized calcium levels below 1.13 mmol/l were considered probable risk factors.

Conclusion. Determined prognostically significant predictors of adverse outcome in patients with acute pancreatitis receiving Reamberin should be considered when selecting inclusion/exclusion criteria for the randomized controlled comparative clinical study of the efficacy of meglumine sodium succinate in patients with acute pancreatitis.

1. Starzl T.E., Donner A., Eliasziw M., Stitt L., Meier P., Fung J.J., McMichael J.P., Todo S. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995; 346 (8986): 1346– 1350. DOI: 10.1016/s0140-6736(95)92349-7

2. Albertson T.E., Sutter M.E., Chan A.L. The acute management of asthma. Clin Rev Allergy Immunol. 2015; 48 (1): 114–125. DOI: 10.1007/s12016-014-8448-5.

3. Vincent J.-L. We should abandon randomized controlled trials in the intensive care unit. Critical Сare Med. 2013; 8: 534–538. DOI 10.1097/ccm.0b013e3181f208ac

4. Greenhalgh T., Howick J., Maskrey N., Evidence Based Medicine Renaissance Group. Evidence based medicine: a movement in crisis? BMJ. 2014; 13 (348): g3725. DOI: 10.1136/bmj.g3725.

5. Rankin A., Cadogan C.A., Patterson S.M., Kerse N., Cardwell C.R., Bradley M.C., Ryan C., Hughes C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018; 9 (9): CD008165. DOI: 10.1002/14651858.CD008165.pub4. PMID: 30175841; PMCID: PMC6513645

6. Xiao A.Y., Tan M.L.Y., Wu L.M. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016; 1: 45–55

7. Crockett S.D., Wani S., Gardner T.B., Falck-Ytter Y., Barkun A.N.; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018; 154 (4): 1096–1101. DOI: 10.1053/j.gastro.2018.01.032.

8. Di M.Y., Liu H., Yang Z.Y., Bonis P.A., Tang J.L., Lau J. Prediction Models of Mortality in Acute Pancreatitis in Adults: A Systematic Review. Ann Intern Med. 2016; 165 (7): 482–490. DOI: 10.7326/M16-0650

9. Buxbaum J. L., Quezada M., Da B., Jani N., Lane C., Mwengela D., Kelly T., Jhun P., Dhanireddy K., Laine L. Early Aggressive Hydration Hastens Clinical Improvement in Mild Acute Pancreatitis. Am J Gastroenterol. 2017; 112 (5): 797–803. DOI: 10.1038/ajg.2017.40

10. Thomson A. Intravenous fluid therapy in acute pancreatitis: a critical review of the randomized trials. ANZ J Surg. 2018; 88 (7–8): 690–696. DOI: 10.1111/ans.14320.

11. Hines O.J., Pandol S.J. Management of severe acute pancreatitis. BMJ. 2019; 367: l6227. Published 2019 Dec 2. DOI: 10.1136/bmj.l6227

12. Gerasimov L.V., Marchenkov Yu.V., Volkov D.P. Possibilities of correction of metabolic disorders using reamberin in the acute period of trauma. Anestesiol. i reanimatol. 2015; 60 (6): 50–54. [In Russ.].

13. Palmer B.F., Clegg D.J. Hyperchloremic normal gap metabolic acidosis. Minerva Endocrinol. 2019; 44 (4): 363–377. DOI: 10.23736/S0391-1977.19.03059-1. PMID: 31347344.

14. Shakh B.N., Lapshin V.N., Kyrnyshev A.G., Smirnov D.B., KravchenkoBerezhnaya N.R. Metabolic Effects of a Succinic Acid. Obshchaya Reanimatologiya=General Reanimatology. 2014; 10 (1): 33–42. [In Russ.]. DOI: 10.15360/1813-9779-2014-1-33-42

15. Lee P.J., Papachristou G.I. Management of Severe Acute Pancreatitis [published online ahead of print]. Curr Treat Options Gastroenterol. 2020; 1–12. DOI: 10.1007/s11938-020-00322-x

16. ROH expert group on acute pancreatitis: Dibirov M. D. (Chairman), Bagnenko S. F., Blagovestnov D.A., Galperin E.I., Dyuzheva T.G., Prudkov M. I., Filimonov M.I., Zhao A.V. Diagnosis and treatment of acute pancreatitis (Russian clinical guidelines). St. Petersburg, 2015 [In Russ.].

17. Greenberg J.A., Hsu J., Bawazeer M., Marshall J., Friedrich J.O., Nathens A., Coburn N., May G.R., Pearsall E., McLeod R.S. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016; 59 (2): 128–140. DOI: 10.1503/cjs.015015

18. Zhiltsov I.V., Semenov V.M., Zenkova S.K. Fundamentals of medical statistics. Biomedical Research Design: A practical guide. Vitebsk: VSMU; 2014: 154. [In Russ.].

19. Grzhibovsky A.M., Ivanov S.V., Gorbatova M.A. Analysis of nominal and rank variable data using Statistica and SPSS software. Nauka I zdravookhraneniye. 2016; 6: 5–39. [In Russ.].

20. Nikolenko A.V., Prelous I.N., Leiderman I.N. Correction of Stress Hyperglycemia in Patients with Acute Surgical Abdominal Diseases. Obshchaya Reanimatologiya=General Reanimatology. 2013; 9 (2): 29. [In Russ.] DOI: 10.15360/1813-9779-2013-2-29

21. Fidkowski C, Helstrom J. Diagnosing metabolic acidosis in the critically ill: bridging the anion gap, Stewart, and base excess methods. Can J Anaesth. 2009; 56 (3): 247–256. DOI: 10.1007/s12630-008-9037-y. PMID: 19247746.

22. Levi M. Platelets in Critical Illness. Semin Thromb Hemost. 2016; 42 (3): 252–257. DOI: 10.1055/s-0035-1570080. PMID: 26926582.

23. Knöbl P. Thrombopenie auf der Intensivstation : Diagnose, Differenzialdiagnose und Therapie [Thrombocytopenia in the intensive care unit: Diagnosis, differential diagnosis, and treatment]. Med Klin Intensivmed Notfmed. 2016; 111 (5): 425–433. German. DOI: 10.1007/s00063-016-0174-8. PMID: 27255225; PMCID: PMC7095953.

24. Lambden S., Laterre P.F., Levy M.M., Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019; 23 (1): 374. DOI: 10.1186/s13054-019-2663-7. PMID: 31775846; PMCID: PMC6880479.

25. Wijdicks E.F., Kramer A.A., Rohs T. Jr., Hanna S., Sadaka F., O’Brien J., Bible S., Dickess S.M., Foss M. Comparison of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in predicting mortality in critically ill patients. Crit Care Med. 2015; 43 (2): 439–444. DOI: 10.1097/CCM.0000000000000707. PMID: 25393699